Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB9 hours ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity
WEB8 hours ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
WEB2 hours ago · In March, Novo Nordisk shared monlunabant update during its Capital Markets Day 2024. In Phase 1, monlunabant produced a statistically significant mean weight loss of 3.5 kg (3.3%) compared to 0.6 ...
Novo Nordisk Stock Declines After Headline Results From Mid …
WEB5 hours ago · Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant ...
Novo Nordisk’s obesity newcomer monlunabant heads into …
WEB6 hours ago · Novo Nordisk has now announced headline results from a Phase IIa trial with monlunabant investigating the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome. People were equally randomized among the four treatment arms.
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
WEB6 hours ago · Friday, shares of Novo Nordisk A/S are sliding following the announcement of safety results of phase 2a clinical trial of Monlunabant compared to placebo in patients with obesity and metabolic syndrome.Monlunabant, formerly INV-202, is a small molecule oral cannabinoid receptor 1 or CB1 inverse agonist. The trial investigated efficacy and safety, and post 16 weeks, people treated with a once ...
Novo Nordisk Experimental Obesity Pill Achieved Limited Extra …
WEB21 hours ago · Based on the results, Novo Nordisk said it expects to initiate a larger Phase 2b trial to further investigate dosing and the safety profile of Monlunabant over a longer duration in a global ...
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
WEB7 hours ago · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk weight loss pill Monlunabant has mood side
WEB6 hours ago · The new drug was tested in once-daily doses of 10mg, 20mg, and 50mg. Starting from an average weight of 110.1 kg (242.7 lbs), participants taking any dose of monlunabant lost significantly more ...
Novo Nordisk's experimental weight loss pill has some ... - Yahoo
WEB5 hours ago · Novo Nordisk stock fell nearly 6% during Friday morning trading after it posted the results. The Danish pharma giant tested monlunabant, a drug it acquired in 2023 with its $1 billion purchase of ...
- Some results have been removed
Skip to content